Parallel comparison of tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples.

Trial Profile

Parallel comparison of tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PartnersPrEP
  • Most Recent Events

    • 22 Aug 2016 According to a Gilead Sciences media release, the European Commission has granted marketing authorisation in the European Union (EU) for once daily Truvada (emtricitabine / tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired human immunodeficiency virus type 1 (HIV-1) infection in adults at high risk based on data from this and iPrEX (CTP 700022550) trials.
    • 22 Jul 2016 According to an European Medicines Agency media release, based on the data from this study, The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Truvada (emtricitabine / tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired human immunodeficiency virus type 1 (HIV-1) infection in adults at high risk.
    • 01 Apr 2016 Results of a sub-group analysis (n=1549) published in the JAIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top